Strategic partnerships Charles River has recently expanded collaboration with multiple biotech players including Medigen Vaccine Biologics and Prestige Biopharma, signaling a strong openness to joint development and outsourcing opportunities that our solutions could support with integration, data sharing, and scalable testing services.

AI and digital pathology The launch of an AI-powered, end-to-end digital pathology solution and participation in TuneLab AI/ML initiatives indicate a growing emphasis on digital modernization and automation, presenting upsell potential for our analytics, cloud, and data management tools.

Revenue and growth momentum With Q2 2026 revenue around the $1B mark and full-year guidance raised, there is evidence of sustained demand for Charles River’s services, creating opportunities for expanded service offerings, higher-value contracts, and cross-sell of integrated research platforms.

Global scale and headcount A 10001+ employee base and active hiring across sites suggest ongoing capacity expansion and need for scalable operational technology, training, and supply-chain optimization solutions that support large, distributed teams.

Strategic acquisitions and assets Recent asset acquisitions and stake acquisitions related to PathoQuest and partnerships with Eurazeo-linked entities indicate a dynamic inorganic growth path, signaling opportunities to provide integration services, due diligence support, and portfolio harmonization offerings.